Opinion|Videos|January 22, 2024
Real-World Effectiveness of Ixazomib Combined With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Present real-world data on the efficacy and safety of the ixazomib-lenalidomide-dexamethasone combination in patients with relapsed/refractory multiple myeloma outside of clinical trials.
Advertisement
Episodes in this series
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
2
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
3
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
4
Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028
5